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Letters to the Editor
International Retinal Laser Society Guidelines For
Subthreshold Laser Treatment
The recent advent of new laser approaches has
revolutionized the laser treatment techniques for retinal
diseases. In particular, the goal of modern subthreshold
laser (STL) treatment is now retinal preservation and
normalization, rather than destruction.1–8 Despite the
proven effectiveness of STL, lack of standardization
has limited its clinical application and usefulness.2–8
The International Retinal Laser Society (LIGHT)
would like to provide simple evidence-based treatment
guidelines to optimize STL application for all users.9
The Target
The target of treatment is the retinal pigment epithe-
lium (RPE). The therapeutic effects of retinal laser are
the result of RPE cell hyperthermia caused by laser
absorption in RPE melanosomes.1–6
Low-Intensity Treatment
All therapeutic effects of STL arise from RPE
cells affected, but not killed, by laser exposure,
through thermal activation and enhanced function of
intra-RPE heat-shock proteins (HSPs).3–6,10 As an
enzymatic threshold phenomenon, the response at the
cellular level is switch-like; “on/off,” all-or-nothing,
rather than graduated.10 Treatment intensities exceed-
ing the HSP activation threshold increase the risk of
retinal damage but do not improve therapeutic effects.
Designed to respond to acute existential threats, HSP
activation is catalytic; initiating reparative cascades
within the cell, locally, and systemically to normal-
ize function.3–6,11 The therapeutic range (TR) is the
zone wherein treatment is therapeutically effective and
safe, sublethal to the retina. The breadth of the TR,
and thus likelihood of clinical treatment safety, varies
markedly depending on laser mode and parameters.4,5
The TR is broadened and safety maximized by use of
longer wavelengths, longer pulse durations, and low-
frequency pulse trains4,5,10 (Table).
High-density Treatment
Normalization of RPE function at the cellular level
requires amplification to achieve and maximize thera-
peutic clinical effects. This is accomplished by conflu-
ent treatment of broad areas of dysfunctional retina
to recruit and normalize the RPE en masse. The most
common error with modern retinal laser therapy is
undertreatment; characterized by too few spot appli-
cations, of insufficient density, over too small areas 2–6
Titration?
Titration of laser treatment intensity is an idea
rooted in the photocoagulation era, which used
immediately visible physical, rather than invisible
physiologic, endpoints. Titration is discouraged
by LIGHT because it increases the likelihood of
unintended retinal damage.4,5 Instead, LIGHT recom-
mends use of published “fixed” laser parameters
(identical settings in all eyes) shown to be reliably safe
and effective (Table).
Technique
Bearing in mind the action of STL is mediated
through the RPE, an extensive RPE area must be
treated to maximize clinical outcomes.4 Thus tradi-
tional targeted focal and local treatment is discour-
aged. For most applications, we consider panmacular
treatment the optimal approach.6 In panmacular treat-
ment, the entire retina between the vascular arcades is
“painted”with confluent laser spots, several times over
in a single treatment session, to ensure complete cover-
age and avoid undertreatment. The number of laser
spots required depends on the spot size. For example,
panmacular treatment with a 125-μm spot may require
2000 shots, whereas a 500-μm spot requires only 400
to 450. STL can be used like a drug to treat the entire
retina, repeated as necessary, and used in conjunction
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Table. Example Treatment Parameters for Various Laser Modes and Settings and Effects on Therapeutic (Clinical
Safety) Ranges
Laser Wavelength Retinal Power Duty Spot Duration Therapeutic
Mode (nm) Spot (um) (Watts) Cycle (%) (Seconds) Rangeg (Watts)
Nanoa 532 400 ∼24(mJ)d CW 3 × 10−9 0
Microb 532 100 ∼ 0.117d CW 0.00002 0.010
MP8 c,e 577 105 0.250 5 0.20 0.29
MP6 c,e 810 210 1.4 5 0.15 4h
MP c,e,f 810 525 1.7 5 0.30 15h





fFixed, currently preferred; used in over 20,000 consecutive panmacular treatments (Luttrull, unpublished data 2020).
gCalculated difference between the laser power at given laser parameters required for reaching the activation threshold of
1.0 for the Arrhenius integrals of the therapeutic reset effect (lower limit of TR) and the 50/50 risk of thermal cell death (upper
limit of TR).
hNote that the TR of these 810nm laser parameters exceed the maximum available power of current retinal lasers allowing
use in all eyes of all patients for all indications, safely and effectively.
with surgery or drugs to maximize management
options and treatment outcomes.
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